Cell Bound Complement Activation Proteins as Markers of Liver Injury

Withdrawn before enrolling

Conditions studied: Hepatitis C

In brief

Subjects who eventually undergo treatment for HCV, we will gather treatment data (start and stop dates), and repeat CB-CAP analysis at weeks 4, 12, 24 and 72 (+/- 2 week window allowed at each time point) to determine whether CB-CAPs levels predict virologic response in treated subjects. Routine laboratory data will also be collected at these time points.

Key facts

Study ID
NCT01025531
Run by
University of Pittsburgh
People needed
0
Starts
2008-12-01
Expected to finish
2014-12-01
Last updated by the study team
2014-12-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.